| Name | Title | Contact Details |
|---|---|---|
Bosco Chiu |
Chief Risk Officer | Profile |
Statline is a Greenwood Vlg, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Integrated Health Network (IHN) of Wisconsin is the state’s first multi-system, clinically integrated accountable care network and one of the first in the United States. It is a consortium of independent health systems, hospitals and physicians working together to improve the quality, efficiency and value of health care. Since its launch in 2010, IHN has been transforming health care delivery with our clinically integrated network of leading health care providers and our sophisticated infrastructure for data analytics. The result is a model that delivers high quality health care and the cost savings of a narrow network, combined with the scale and value only possible through the breadth of a larger system.
Valley Eldercare Ctr-Valley is a Grand Forks, ND-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic